COX-1 and COX-2 inhibition: current status and future perspective.
Greyn
J
J
Department of Anesthesiology, Flemish Free University of Brussels School of Medicine, Belgium.
Lauwers
M H
MH
Vanlersberghe
C
C
Camu
F
F
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D005544:Forecasting; D006801:Humans; D006930:Hyperalgesia / Q000503:physiopathology; D007527:Isoenzymes / Q000187:drug effects* / Q000502:physiology; D008565:Membrane Proteins; D010146:Pain / Q000188:drug therapy; D010544:Peroxidases / Q000037:antagonists & inhibitors* / Q000187:drug effects / Q000502:physiology; D011451:Prostaglandin-Endoperoxide Synthases / Q000187:drug effects* / Q000502:physiology; D015290:Second Messenger Systems / Q000187:drug effects / Q000502:physiology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D010544:Peroxidases; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; C496511:PTGS1 protein, human; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases